Y Intercept Hong Kong Ltd Increases Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Y Intercept Hong Kong Ltd increased its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) by 136.9% in the 2nd quarter, according to the company in its most recent filing with the SEC. The fund owned 336,095 shares of the biotechnology company’s stock after acquiring an additional 194,230 shares during the quarter. Y Intercept Hong Kong Ltd owned about 0.16% of BioCryst Pharmaceuticals worth $3,011,000 as of its most recent SEC filing.

Other large investors also recently added to or reduced their stakes in the company. Headlands Technologies LLC purchased a new stake in BioCryst Pharmaceuticals in the 1st quarter worth about $32,000. New Age Alpha Advisors LLC purchased a new stake in BioCryst Pharmaceuticals in the 1st quarter worth about $62,000. Family Legacy Financial Solutions LLC purchased a new stake in BioCryst Pharmaceuticals in the 2nd quarter worth about $72,000. Allspring Global Investments Holdings LLC purchased a new position in BioCryst Pharmaceuticals during the 1st quarter valued at about $79,000. Finally, R Squared Ltd grew its holdings in BioCryst Pharmaceuticals by 84.2% during the 1st quarter. R Squared Ltd now owns 11,670 shares of the biotechnology company’s stock valued at $88,000 after buying an additional 5,335 shares in the last quarter. Hedge funds and other institutional investors own 85.88% of the company’s stock.

BioCryst Pharmaceuticals Price Performance

NASDAQ:BCRX opened at $7.25 on Friday. The business has a 50 day moving average of $7.62 and a 200 day moving average of $8.67. The company has a market capitalization of $1.52 billion, a price-to-earnings ratio of -40.28 and a beta of 1.05. BioCryst Pharmaceuticals, Inc. has a 1-year low of $6.00 and a 1-year high of $11.31.

BioCryst Pharmaceuticals (NASDAQ:BCRX) last released its earnings results on Monday, August 4th. The biotechnology company reported $0.15 earnings per share for the quarter, topping analysts’ consensus estimates of $0.03 by $0.12. The firm had revenue of $163.35 million during the quarter, compared to the consensus estimate of $149.59 million. The business’s quarterly revenue was up 49.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned ($0.06) EPS. As a group, sell-side analysts anticipate that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

Insiders Place Their Bets

In related news, Director Theresa Heggie sold 70,000 shares of the business’s stock in a transaction that occurred on Wednesday, August 13th. The stock was sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the sale, the director owned 65,352 shares in the company, valued at $556,145.52. The trade was a 51.72% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. 5.10% of the stock is owned by insiders.

Wall Street Analyst Weigh In

A number of research analysts have weighed in on BCRX shares. Evercore ISI reaffirmed an “in-line” rating and set a $8.00 target price on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 1st. Needham & Company LLC lifted their target price on BioCryst Pharmaceuticals from $17.00 to $20.00 and gave the company a “buy” rating in a report on Wednesday, October 15th. JMP Securities lifted their target price on BioCryst Pharmaceuticals from $17.00 to $27.00 and gave the company a “market outperform” rating in a report on Wednesday, October 15th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of BioCryst Pharmaceuticals in a report on Wednesday, October 8th. Finally, TD Cowen began coverage on BioCryst Pharmaceuticals in a research report on Wednesday, October 15th. They set a “buy” rating and a $30.00 price target for the company. One analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $19.18.

BioCryst Pharmaceuticals Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.